glp-1 receptor agonist market top selling drugs us Agonists Report 2025-2033, By Product, Molecule, and Geo GLP-1 Receptor Agonist Market: Exploring

All GLP-1 RAs other than Saxenda and Wegovy have the indication of T2DM and are subsidized only for patients with T2DM who first tried metformin, sulphonylureas or insulin, or where these are not appropriate

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways

In 2022, some of the top-selling drugs in this category were Novos Ozempic (US$ 8.7 billion), Lilly and partner Dainippon Sumitomos Trulicity (US$ 7.7 billion), Novos Victoza (US$ 1.8 billion), and Rybelsus (US$ 1.6 billion)

Perhaps most notably for many patients, GLP-1 receptor agonists act on appetite centers in the brain, promoting satiety and reducing food intake

Below, we review the current landscape of oral GLP-1 drugs, how they work, and how they compare to their injectable counterparts

[PubMed] [Google Scholar] 880.Neidigh J.W., Fesinmeyer R.M., Prickett K.S., Andersen N.H